Dravet Syndrome Treatment Monitoring and Goals for Long-Term Management

This episode, titled “Dravet Syndrome Treatment Monitoring and Goals for Long-Term Management,” features panelists discussing the practical considerations that guide treatment selection and ongoing management for patients with Dravet syndrome. Expert faculty review the factors clinicians must weigh when choosing among available therapies, including administration requirements, monitoring needs, adverse effect profiles, drug-drug interactions, and the potential impact of treatment on developmental and behavioral outcomes.

The discussion highlights the importance of individualized treatment planning throughout the lifespan. Panelists review key monitoring considerations associated with commonly used therapies, including cardiovascular surveillance with fenfluramine and laboratory monitoring for hepatic toxicity when therapies such as valproate, cannabidiol, and stiripentol are used in combination. Faculty also discuss the importance of evaluating treatment tolerability, balancing seizure control against medication-related adverse effects, and considering patient-specific factors such as age, comorbidities, reproductive health, and caregiver burden.

Beyond seizure reduction, expert faculty emphasize the broader goals of care in Dravet syndrome, including reducing the risk of status epilepticus and sudden unexpected death in epilepsy (SUDEP), preserving quality of life, supporting independence when possible, and addressing the evolving needs of both patients and caregivers. The panel explores how treatment goals may change as patients transition into adulthood, where long-term care planning, family support, and social considerations often become increasingly important.

Throughout the conversation, panelists stress the importance of shared decision-making and setting realistic but ambitious treatment goals. While Dravet syndrome remains a drug-resistant epilepsy for many patients, expert faculty note that modern treatment approaches have significantly improved outcomes, allowing some patients to achieve prolonged periods of seizure freedom and improved quality of life.

In the next episode, “Unmet Needs and the Impact of Disease Modifying Therapies in Dravet Syndrome,” panelists will examine the persistent gaps that remain despite advances in currently available antiseizure therapies. The discussion highlights how disease-modifying treatments may offer an opportunity to move beyond symptom management and alter the long-term course of Dravet syndrome through earlier and more targeted intervention.